Presentation is loading. Please wait.

Presentation is loading. Please wait.

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation 

Published by Modified over 5 years ago

Similar presentations

Presentation on theme: "First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation "— Presentation transcript:

1 First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation  Paul J. Martin, J. Douglas Rizzo, John R. Wingard, Karen Ballen, Peter T. Curtin, Corey Cutler, Mark R. Litzow, Yago Nieto, Bipin N. Savani, Jeffrey R. Schriber, Paul J. Shaughnessy, Donna A. Wall, Paul A. Carpenter  Biology of Blood and Marrow Transplantation  Volume 18, Issue 8, Pages (August 2012) DOI: /j.bbmt Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Relationship between number of patients enrolled and the Kaplan-Meier estimate of survival at 6 months for each study of initial systemic therapy. The horizontal line shows the weighted average 6-month survival estimate for all studies with standard-dose glucocorticoid treatment. Curved lines approximate the upper and lower boundaries of the 95% confidence interval for the weighted average at any given number of patients enrolled in a study. Squares indicate results of the experimental arms in phase 3 studies, and diamonds indicate results of prospective phase 2 studies and pilot studies. Points between the upper and lower boundaries identify studies with results that are statistically consistent with the weighted average. The point below the lower boundary identifies a study with outlier 6-month survival results that are statistically inconsistent with the weighted average. The asterisk indicates a phase III study that showed a statistically significant difference in survival between the 2 arms. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Relationship between number of patients enrolled and the overall complete response (CR) rate for each study of initial systemic therapy. The horizontal line shows the overall CR rate for all studies with standard-dose glucocorticoid treatment. Curved lines approximate the 95% confidence limits for the overall CR rate at any given number of patients enrolled. Squares indicate results of the experimental arm in phase 3 studies, and diamonds indicate results of prospective phase 2 studies and pilot studies. The asterisk indicates a phase II study that showed a statistically significant improvement in the CR rate compared to historical controls at the same institution. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Relationship between number of patients enrolled and the overall complete response/partial response (CR/PR) rate for each study of initial systemic therapy. The horizontal line shows the overall PR/CR rate for all studies with standard-dose glucocorticoid treatment. Curved lines approximate the 95% confidence limits for the overall PR/CR rate at any given number of patients enrolled. Squares indicate results of the experimental arm in phase 3 studies, and diamonds indicate results of prospective phase 2 studies and pilot studies. The asterisk indicates a phase III study that showed a statistically significant difference in the CR/PR rate between the 2 arms. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Relationship between number of patients enrolled and the Kaplan-Meier estimate of survival at 6 months for each study of second-line therapy. The horizontal line shows the weighted average 6-month survival estimate for all studies. Curved lines approximate the 95% confidence limits for the weighted average at any given number of patients enrolled. Squares indicate prospective studies, and diamonds indicate retrospective studies. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 Relationship between number of patients enrolled and the overall complete response (CR) rate for each study of second-line therapy. The horizontal line shows the overall CR rate for all studies. Curved lines approximate the 95% confidence limits for the overall CR rate at any given number of patients enrolled. Squares indicate prospective studies, and diamonds indicate retrospective studies. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

7 Figure 6 Relationship between the number of patients enrolled and the complete response/partial response (CR/PR) rate for each study of second-line therapy. The horizontal line shows the overall PR/CR rate for all studies. Curved lines approximate the 95% confidence limits for the overall PR/CR rate at any given number of patients enrolled. Squares indicate prospective studies, and diamonds indicate retrospective studies. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation "

Similar presentations

Stephanie J. Lee, Loretta A. Williams 

Stephanie J. Lee, Loretta A. Williams 
Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.
Ulas D. Bayraktar, Denái R. Milton, Elizabeth J

Ulas D. Bayraktar, Denái R. Milton, Elizabeth J
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis  Mohamed A. Kharfan-Dabaja,

Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis  Mohamed A. Kharfan-Dabaja,
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years  Areej El-Jawahri, Shuli Li, Joseph.

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years  Areej El-Jawahri, Shuli Li, Joseph.
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease  Fevzi F. Yalniz, Mehrdad Hefazi, Kristen.

Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease  Fevzi F. Yalniz, Mehrdad Hefazi, Kristen.
Therapy of Sclerodermatous Chronic Graft-Versus-Host Disease with Mammalian Target of Rapamycin Inhibitors  Zuzana Jedlickova, Irina Burlakova, Gesine.

Therapy of Sclerodermatous Chronic Graft-Versus-Host Disease with Mammalian Target of Rapamycin Inhibitors  Zuzana Jedlickova, Irina Burlakova, Gesine.
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,
Generic Immunosuppressants in Hematopoietic Cell Transplantation

Generic Immunosuppressants in Hematopoietic Cell Transplantation
A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease  Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,

A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease  Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,
A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease  Paul A. Carpenter,

A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease  Paul A. Carpenter,
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed.

Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed.
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients 60-75 Years of Age with Secondary Acute.

Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.
Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease  Paul A. Carpenter, Paul Hoffmeister, Charles.

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease  Paul A. Carpenter, Paul Hoffmeister, Charles.
Carol Ann Huff, Ephraim J. Fuchs, B

Carol Ann Huff, Ephraim J. Fuchs, B

Similar presentations

Ads by Google